In fact, with the accumulation of additional data from different patient datasets, it seems that the slight biological and prognostic differences between HER2-low and HER2-0 tumors that were initially described, are essentially related to confounding factors, due to their different respective frequencies among HR+ and HR– breast tumors [15, 16]. This evidence concerns the gene ERBB2 and breast neoplasm.